Mark Wayne Ball MD FACS

Minimally Invasive Surgery, Surgical Oncology

Associate Professor. Associate Program Director, Urologic Oncology Fellowship, Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health

Join to View Full Profile

10 Center DriveBethesda, MD 20892

Summary

Dr. Mark Ball is a board-certified urologist in Bethesda, MD and is affiliated with National Institutes of Health Clinical Center. He received his medical degree from Johns Hopkins University School of Medicine and has been in practice 7 years. He specializes in minimally invasive surgery and surgical oncology and is experienced in kidney cancer, adrenal surgery, and retroperitoneal lymph node dissection.

Education & Training

National Institutes of Health Clinical CenterFellowship, Urologic Surgical Oncology, 2016 - 2018
Johns Hopkins UniversityResidency, Urology, 2011 - 2016
Johns Hopkins UniversityInternship, Surgery, 2010 - 2011
Johns Hopkins University School of MedicineClass of 2010

Certifications & Licensure

MD State Medical License 2013 - 2026
DC State Medical License 2017 - 2018
American Board of Urology Urology

Awards, Honors, & Recognition

Resident Teaching Award Department of Urology, Johns Hopkins University, 2016
Alpha Omega Alpha Medical Honor Society 2015
Member Alpha Omega Alpha, 2014
Outstanding Laparoendoscopic Resident Surgeon Award Johns Hopkins Hopsital, 2013
House Staff Teaching Award Johns Hopkins School of Medicine, 2012
Outstanding Junior Resident Teacher Department of Surgery, Johns Hopkins University, 2011
Member Phi Beta Kappa, 2010
Join now to see all

Clinical Trials

A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer Start of enrollment: 2010 May 06
COMPLETED
PHASE2
Robot-Assisted MRI-Guided Prostate Biopsy Start of enrollment: 2013 Jul 25
Completed
Not Applicable
Study of 99mTc-Sestamibi SPECT/CT Imaging for the Preoperative Diagnosis of Renal Oncocytoma Start of enrollment: 2014 May 01
Completed
Not Applicable
The Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry
RECRUITING
MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003) Start of enrollment: 2017 Apr 24
COMPLETED
PHASE2
Join now to see all

Publications & Presentations

PubMed

Under Pressure: A Quality Improvement Initiative to Reduce Rhabdomyolysis and Hospital-Acquired Pressure Injuries After Retroperitoneal Surgery.
Matthew Miller, Lauren Loebach, Ruben Blachman-Braun, Daniel Nethala, Braden Millan
Urology Practice. 2025-11-01
SNMMI/EANM/ACNM Procedure Standard/Procedure Guideline on the Use of Molecular Imaging for Renal Mass Characterization.
Steven P Rowe, Brian M Shuch, Mark W Ball, Axel Bex, Mehrbod S Javadi
Journal of Nuclear Medicine. 2025-10-09
Is Active Surveillance a Suitable Approach for Bilateral Multifocal Renal Oncocytomas? The 20-Year National Cancer Institute Experience.
Aditi Chaurasia, Shiva Singh, Noah Pinson, Nikhil Gopal, Jessica Hsueh
Clinical Genitourinary Cancer. 2025-10-01

Press Mentions

Non-Surgical Option Approved for Recurrent Low-Grade Bladder CancerJune 12th, 2025
Decision Making During Complex Partial Nephrectomy: A Guidelines-Based ApproachMarch 21st, 2021
AUA 2018: Kidney Cancer Tumor BoardMay 19th, 2018
Join now to see all

Grant Support

Clinical Research GrantIntuitive Surgery2013–2014

Research History

Fellow, Urologic OncologyLaboratory of W. Marson Linehan, MD. Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute2016 - 2018
Research FellowJames Buchanan Brady Urological Institute2013 - 2014